BBIQ

CAS No. 1229024-57-0

BBIQ( —— )

Catalog No. M26625 CAS No. 1229024-57-0

BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
25MG 47 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BBIQ
  • Note
    Research use only, not for human use.
  • Brief Description
    BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7.
  • Description
    BBIQ is a powerful vaccine adjuvant that enhances innate immune responses[2] and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7.(In Vitro):BBIQ induces IFN-α in human PBMCs (520 pg/mL at 5 μg/mL).(In Vivo):In mice treated with Chloroquine (CQ) alone, parasite (P. berghei ANKA) appearesd on Day 17 and all mice of this group died by Day 21. Mice treated with BBIQ along with CQ exhibits no appearance of parasite till Day 23. Frequencies of T cells (CD3+, CD4+and CD8+) and T regulatory cells (CD4+, CD25 +and FoxP3+) are lower in brain of BBIQ + CQ treated mice as compared to BBIQ alone and CQ alone treated mice on Day 10. Serum levels of IFN-γ and IL-12 are higher on same day in mice treated with BBIQ + CQ which reveals the generation of strong Th1 immune response in mice against the infection. Inhibition of infiltration of inflammatory T cells and activation of T helper and T cytotoxic cells against the parasite is observed in the mice treated with this combination therapy.
  • In Vitro
    BBIQ induces IFN-α in human PBMCs (520?pg/mL at 5?μg/mL).
  • In Vivo
    In mice treated with Chloroquine (CQ) alone, parasite (P. berghei ANKA) appearesd on Day 17 and all mice of this group died by Day 21. Whereas, mice treated with BBIQ along with CQ exhibits no appearance of parasite till Day 23. Frequencies of T cells (CD3+, CD4+and CD8+) and T regulatory cells (CD4+, CD25 +and FoxP3+) are lower in brain of BBIQ?+?CQ treated mice as compared to BBIQ alone and CQ alone treated mice on Day 10. Inhibition of infiltration of inflammatory T cells and activation of T helper and T cytotoxic cells against the parasite is observed in the mice treated with this combination therapy. Serum levels of IFN-γ and IL-12 are higher on same day in mice treated with BBIQ?+?CQ which reveals the generation of strong Th1 immune response in mice against the infection.
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    B. anthracis| S. aureus
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1229024-57-0
  • Formula Weight
    330.435
  • Molecular Formula
    C21H22N4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 16.67 mg/mL (50.45 mM)
  • SMILES
    CCCCc1nc2c(N)nc3ccccc3c2n1Cc1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Guo J, et al. Isolation, characterization and antimicrobial activities of polyacetylene glycosides from Coreopsis tinctoria Nutt. Phytochemistry. 2017 Apr;136:65-69.
molnova catalog
related products
  • RS09 2TFA 1449566-36...

    RS09 2TFA is a TLR4 agonist.?Promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro.??It acts as an adjuvant in vivo and enhances X-15 specific antibody serum concentrations.

  • Gardiquimod

    Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells.

  • BMS-905

    BMS-905 is a potent dual inhibitors of TLR7 and TLR8 with good selectivity against TLR9 and other family members. BMS-905 can be used in studies about the treatment of diseases such as psoriasis, arthritis, and lupus.